Sign in
TerminatedNo phase

Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy

Key facts

Who runs it
Institut Cancerologie de l'Ouest
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
13 people enrolled
Started
17 Oct 2022
Ended
5 Nov 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sophrology
  • Speech therapy
Record updated
14 April 2026
Why it stopped
Recruitment difficulties

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Patients with histologically proven grade III and IV glial tumours requiring speech therapy
  • Patient willing to start outpatient speech therapy
  • Patient aged 18 years and over
  • Informed patient who has signed consent
  • Patient affiliated to a social security scheme

Who cannot take part

  • Patient unable to follow the protocol (filling in questionnaires, attendance of sophrology and/or speech therapy sessions) for geographical, social or psychological reasons
  • Patients suffering from psychiatric disorders; delusional phases, schizophrenia against the practice of sophrology
  • Patient who has already had an initiation to sophrology in the context of his pathology
  • Performance Status ≥ 4
  • Patients who do not speak French
  • Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian
  • Women who are pregnant, likely to be pregnant or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with brain tumours experience a loss of independence, which may occur suddenly or gradually. Communication with the patient may be rapidly impaired, due to impaired alertness, language and/or neurocognitive disorders.

Read full original descriptionShow less

In addition to these clinical symptoms, there is a high level of anxiety and depression in this population due to the severity of the diagnosis, with a major impact on the patients' quality of life. In this study, we are mainly interested in the proportion of this population with communication disorders where speech therapy is important In order to better take into account anxiety, which is often difficult to verbalise due to communication problems, sophrology can be proposed as an alternative to psychological support, which is often too complicated or inappropriate.

After having noted positive feedback from patients after joint speech therapy and sophrology treatment, we wish to evaluate the interest of coupling sophrology treatment for patients with glial tumours requiring speech therapy.

Our hypothesis is that this association would improve the level of anxiety, the quality of life and have a positive impact on the patient's speech therapy.

The 2 groups in the trial

  • Experimental arm : Speech therapy + SophrologyTreatment being tested

    In the experimental arm, patients will receive 6 sessions of sophrology. The sessions are individual and last approximately 50 minutes. In addition to the sophrology sessions, patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.

    Treatment: Sophrology and Speech therapy

  • Control arm : Speech therapyExisting treatment, for comparison

    Patients will benefit from two speech therapy sessions per week for 6 months, lasting from 30 minutes to 1 hour depending on the patient's general condition.

    Treatment: Speech therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 April 2026